UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Role of early repeated renal biopsies in lupus nephritis

Lupus science & medicine, 2014, Vol.1 (1), p.e000018-e000018

2014

Volltextzugriff (PDF)

POS0779 MYOCARDIAL INFARCTIONS, SUBTYPES, LOCATIONS AND CORONARY ATHEROSCLEROSIS IN SLE - A COMPARATIVE STUDY WITH MATCHED CONTROLS

Annals of the rheumatic diseases, 2021-06, Vol.80 (Suppl 1), p.643-643

2021

Volltextzugriff (PDF)

Regional European genetic ancestry predicts type I interferon level and risk of severe viral infection

QJM : An International Journal of Medicine, 2024-08, Vol.117 (8), p.581-588

2024

Volltextzugriff (PDF)

Long-term follow-up in lupus nephritis patients treated with rituximab--clinical and histopathological response

Rheumatology (Oxford, England), 2013-05, Vol.52 (5), p.847-855

2013

Volltextzugriff (PDF)

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

The Lancet (British edition), 2009-08, Vol.374 (9688), p.459-466

2009

Volltextzugriff (PDF)

THU0381 High levels of circulating type i, ii and iii interferons define distinct patient subsets with active systemic lupus erythematosus (SLE)

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.406

2018

Volltextzugriff (PDF)

Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus – distinct roles of BAFF and APRIL

Lupus, 2018-08, Vol.27 (9), p.1470-1478

2018

Volltextzugriff (PDF)

Serum soluble tumour necrosis factor receptor-2 (sTNFR2) as a biomarker of kidney tissue damage and long-term renal outcome in lupus nephritis

Scandinavian journal of rheumatology, 2017-07, Vol.46 (4), p.263-272

2017

Volltextzugriff (PDF)

FRI0309 The impact of belimumab and rituximab on health-related quality of life in patients with systemic lupus erythematosus

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.691

2018

Volltextzugriff (PDF)

Clinical manifestations and anti-phospholipid antibodies in 712 patients with systemic lupus erythematosus: evaluation of two diagnostic assays

Rheumatology (Oxford, England), 2013-03, Vol.52 (3), p.501-509

2013

Volltextzugriff (PDF)

FRI0310 Serum Insulin-like Growth Factor-Binding Protein 2 (IGFBP2) as A Biomarker of Clinical and Histopathological Treatment Response in Lupus Nephritis

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.547-547

2016

Volltextzugriff (PDF)

AB0458 Serum Ferritin as A Biomarker of Clinical and Histopathological Response To Treatment in Lupus Nephritis

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.1063-1063

2016

Volltextzugriff (PDF)

Increased Serum Levels of IFN-Λ Correlate with Th17 Axis Cytokines and Independently To IFN-α Identify Patient Group with Higher Organ Damage

ANNALS OF THE RHEUMATIC DISEASES, 2016, Vol.75, p.128

2016

Volltextzugriff (PDF)

S13.2 Anti-phosphatidylserine/prothrombin antibodies and thrombosis associate positively with hHLA-DRB1 13 and negatively with HLA-DRB103 in SLE

Lupus science & medicine, 2022-10, Vol.9 (Suppl 2), p.A19-A19

2022

Volltextzugriff (PDF)

S12.1 Il-16 – a urinary biomarker for proliferative lupus nephritis

Lupus science & medicine, 2022-10, Vol.9 (Suppl 2), p.A17-A17

2022

Volltextzugriff (PDF)

THU0520 Interferon (IFN)-Lambda1/3, but not IFN-Alpha, is A Marker of Poor Response to Treatment in Lupus Nephritis

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.363-363

2014

Volltextzugriff (PDF)

SAT0401 Antiphospholipid Antibodies in Lupus Nephritis and Their Role in Long-Term Outcome

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.804-804

2015

Volltextzugriff (PDF)

SAT0383 Microparticles in 290 SLE Patients and Matched Controls and Their Relationship to Vascular Disease

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.798-798

2015

Volltextzugriff (PDF)

High Anti-Dsdna Content in Sle Immune Complexes is associated with Clinical Remission Following Belimumab Treatment

ANNALS OF THE RHEUMATIC DISEASES, 2017, Vol.76, p.861

2017

Volltextzugriff (PDF)

THU0162 Thrombotic microangiopathy in renal biopsies from patients with systemic lupus erythematosus

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.210-210

2013

Volltextzugriff (PDF)

THU0530 Blys and APRIL in Lupus Nephritis: Correlations with Serology - Blys as A Non-Invasive Predictor of Response

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.366-366

2014

Volltextzugriff (PDF)

FRI0014 Multiplex Screening of Cytokines in The Search for Disease Activity Markers of SLE

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.430-431

2016

Volltextzugriff (PDF)

PO.8.176 Inflammation in blood and placenta in SLE pregnancies

Lupus science & medicine, 2022-10, Vol.9 (Suppl 2), p.A125-A125

2022

Volltextzugriff (PDF)

High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus

Arthritis research & therapy, 2019-04, Vol.21 (1), p.107-107, Article 107

2019

Volltextzugriff (PDF)

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial

The Lancet (British edition), 2012, Vol.379 (9827), p.1712-1720

2012

Volltextzugriff (PDF)

1 – 25 von 241

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(216)
Mit Volltextzugriff
(189)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(238)
Deutsch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Role of early repeated renal biopsies in lupus nephritis

POS0779 MYOCARDIAL INFARCTIONS, SUBTYPES, LOCATIONS AND CORONARY ATHEROSCLEROSIS IN SLE - A COMPARATIVE STUDY WITH MATCHED CONTROLS

Regional European genetic ancestry predicts type I interferon level and risk of severe viral infection

Long-term follow-up in lupus nephritis patients treated with rituximab--clinical and histopathological response

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

THU0381 High levels of circulating type i, ii and iii interferons define distinct patient subsets with active systemic lupus erythematosus (SLE)

Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus – distinct roles of BAFF and APRIL

Serum soluble tumour necrosis factor receptor-2 (sTNFR2) as a biomarker of kidney tissue damage and long-term renal outcome in lupus nephritis

FRI0309 The impact of belimumab and rituximab on health-related quality of life in patients with systemic lupus erythematosus

Clinical manifestations and anti-phospholipid antibodies in 712 patients with systemic lupus erythematosus: evaluation of two diagnostic assays

FRI0310 Serum Insulin-like Growth Factor-Binding Protein 2 (IGFBP2) as A Biomarker of Clinical and Histopathological Treatment Response in Lupus Nephritis

AB0458 Serum Ferritin as A Biomarker of Clinical and Histopathological Response To Treatment in Lupus Nephritis

Increased Serum Levels of IFN-Λ Correlate with Th17 Axis Cytokines and Independently To IFN-α Identify Patient Group with Higher Organ Damage

S13.2 Anti-phosphatidylserine/prothrombin antibodies and thrombosis associate positively with hHLA-DRB1 13 and negatively with HLA-DRB103 in SLE

S12.1 Il-16 – a urinary biomarker for proliferative lupus nephritis

THU0520 Interferon (IFN)-Lambda1/3, but not IFN-Alpha, is A Marker of Poor Response to Treatment in Lupus Nephritis

SAT0401 Antiphospholipid Antibodies in Lupus Nephritis and Their Role in Long-Term Outcome

SAT0383 Microparticles in 290 SLE Patients and Matched Controls and Their Relationship to Vascular Disease

High Anti-Dsdna Content in Sle Immune Complexes is associated with Clinical Remission Following Belimumab Treatment

THU0162 Thrombotic microangiopathy in renal biopsies from patients with systemic lupus erythematosus

THU0530 Blys and APRIL in Lupus Nephritis: Correlations with Serology - Blys as A Non-Invasive Predictor of Response

FRI0014 Multiplex Screening of Cytokines in The Search for Disease Activity Markers of SLE

PO.8.176 Inflammation in blood and placenta in SLE pregnancies

High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial

Suchergebnisse filtern